rss
Br J Ophthalmol doi:10.1136/bjo.2007.123513

Intravitreal Bevacizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion

  1. Thomas C Kreutzer (thomas.kreutzer{at}med.uni-muenchen.de),
  2. Claudia S Alge (claudia.alge{at}med.uni-muenchen.de),
  3. Armin H Wolf (armin.wolf{at}med.uni-muenchen.de),
  4. Daniel Kook (daniel.kook{at}med.uni-muenchen.de),
  5. Johannes Burger (johannes.burger{at}med.uni-muenchen.de),
  6. Rupert Strauß (rupert.strauss{at}med.uni-muenchen.de),
  7. Christian Kunze (christian.kunze{at}i-med.ac.at),
  8. Christos Haritoglou (christos.haritoglou{at}med.uni-muenchen.de),
  9. Anselm Kampik (anselm.kampik{at}med.uni-muenchen.de),
  10. Siegfried G Priglinger (siegfried.priglinger{at}med.uni-muenchen.de)
  1. LMU Munich, Germany
  2. LMU Munich, Germany
  3. LMU Munich, Germany
  4. LMU Munich, Germany
  5. LMU Munich, Germany
  6. LMU Munich, Germany
  7. University Innsbruck, Austria
  8. LMU Munich, Germany
  9. LMU Munich, Germany
  10. LMU Munich, Germany
    • Published Online First 22 January 2008

    Abstract

    Purpose: To evaluate the effect of intravitreal bevacizumab (Avastin®) injections on visual acuity (VA) and foveal retinal thickness in patients with macular oedema secondary to branch retinal vein occlusion (BRVO).

    Methods: A prospective, non comparative, consecutive, interventional case series of thirty four patients. Patients received repeated intravitreal injections of 1.25mg bevacizumab. Main outcome measures were VA (Snellen charts and ETDRS) and optical coherence tomography measurements in a follow up period of 6 months.

    Results: Patients presented at a mean age of 69 years (range 44 – 86 years). Mean duration of symptoms was 40 weeks (range 1 – 300 weeks). Visual acuity at baseline was 0.79 LogMAR (±0.39) and improved to a mean of 0.46 LogMAR (±0.38) at the six month control (P = 0.009). Mean letter score on the ETDRS-chart at baseline was 45.3 (±19.0) and improved to a mean of 65.3 (±20.6) letters at the six month control visit (P = 0.003). Retinal thickness as measured by OCT at baseline was 473µm (±120) and declined to a mean of 326µm (±90) at the six month control.

    Conclusion: Intravitreal injection of 1.25mg bevacizumb appears to be an effective treatment option for BRVO.

    Relevant Article

    • At a glance:At a glance
      • Harminder S Dua,
      • Arun D Singh, Editors-in-Chief
      Br J Ophthalmol 2008;92:301

    This Article

    1. Abstract
    2. PDF
    3. All versions of this article:
      1. bjo.2007.123513v1
      2. 92/3/351most recent

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.